title: Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant mice.
abstract: The objective of this study was to determine whether the development of tolerance to CP 55,940, a potent cannabinoid agonist, was due to changes in the receptor or second messenger system. ICR mice treated with CP 55,940 (2 mg/kg) twice a day for 6 and one-half days developed a high degree of tolerance to the pharmacological effects of CP 55,940. The ability of CP 55,940 to produce motor hypoactivity, hypothermia and immobility was reduced 163-, 97- and 19-fold, respectively. Evaluation of 3H-CP 55,940 binding to rat brain membranes indicated no difference in receptor affinity between the vehicle- and CP 55,940-treated animals. However, these binding studies revealed a 50% decrease in receptor number in the cerebellum of the CP 55,940-tolerant mice. Although cAMP is generally considered to be the second messenger for cannabinoid receptors, little difference was observed in the inhibitory effects of CP 55,940 on adenylyl cyclase activity in cerebellum between vehicle and drug-treated mice. However, there was an increase in receptor mRNA which suggests a compensation for receptor loss. There are several possible explanation for these results. There may be sufficient spare receptors such that CP 55,940-tolerant mice are capable of producing a maximal effect on the second messenger system. On the other hand, one could conclude that cannabinoid receptor down-regulation does not account for the development of tolerance to all of the effects of CP 55,940 in mice.
authors.affiliation: Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond 23298-613, USA.
authors.forename: F
authors.initials: F
authors.lastname: Fan
authors.forename: Q
authors.initials: Q
authors.lastname: Tao
authors.forename: M
authors.initials: M
authors.lastname: Abood
authors.forename: B R
authors.initials: BR
authors.lastname: Martin
mesh_terms: D000067956:Adenylyl Cyclase Inhibitors; D000818:Animals; D001833:Body Temperature Regulation / Q000187:drug effects; D002186:Cannabinoids / Q000494:pharmacology*; D002531:Cerebellum / Q000187:drug effects*; D005576:Colforsin / Q000494:pharmacology; D003511:Cyclohexanols / Q000494:pharmacology*; D015536:Down-Regulation; D004361:Drug Tolerance; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009043:Motor Activity / Q000187:drug effects; D012333:RNA, Messenger / Q000032:analysis; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000819:agonists*; D013045:Species Specificity
chemical_list: D000067956:Adenylyl Cyclase Inhibitors; D002186:Cannabinoids; D003511:Cyclohexanols; D004791:Enzyme Inhibitors; D012333:RNA, Messenger; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; D005576:Colforsin; C054649:3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol